c
2
12
18
28
12
12
1a
14
e
12
16
a
a
2
2
a
20
32
1a
2a
19
Faculty
61 16
19
1
49
2
2
1a
32
34
1b
1d
18
39
6f
1d
2 29
1d
25
Hamideh Parhiz, PharmD, PhD
78
6f
Assistant Professor of Systems Pharmacology and Translational Therapeutics
7
8a
Department: Systems Pharmacology and Translational Therapeutics
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
41
4
3
3
3
2
4
b
1f
41
421 Curie Boulevard
35 Biomedical Research Building II/III Room 1256
59 University of Pennsylvania Perelman School of Medicine
Philadelphia, PA 19104
26
35 Biomedical Research Building II/III Room 1256
59 University of Pennsylvania Perelman School of Medicine
Philadelphia, PA 19104
35
ab
12
13
Education:
21 b PharmD 15 (Pharmacy) c
45 Mashhad University of Medical Sciences, Iran, 2005.
21 8 PhD 29 (Pharmaceutical Biotechnology) c
45 Mashhad University of Medical Sciences, Iran, 2011.
c
3
3
3
3
92
Permanent link21 b PharmD 15 (Pharmacy) c
45 Mashhad University of Medical Sciences, Iran, 2005.
21 8 PhD 29 (Pharmaceutical Biotechnology) c
45 Mashhad University of Medical Sciences, Iran, 2011.
c
2 29
21
1e
1d
24
76
18 Nano-engineering
29 Targeted delivery of nanomedicine
19 mRNA therapeutics
14 Autoimmunity
2b Cancer Immunology and Immunotherapy
8
1b Research Interests:
2fd Our lab develops novel nucleic acid delivery systems, including a new generation of targeted lipid nanoparticle (tLNP), for in vivo cellular reprogramming. We leverage these systems for mRNA-based therapeutics in a variety of non-vaccine applications such as inherited diseases, acquired or congenital hematopoietic conditions, cancers, fibrosis, and acute inflammatory conditions. We also investigate the mechanisms underlying the enhancement of delivery systems such as the ones related to more favorable pharmacokinetic profile, to apply those principles in designing more effective gene and mRNA therapeutics. Currently, the targeted LNP-mRNA platform we design serves as the foundation for ongoing academic programs and industrial product developments.
e 29
27
Description of Research Expertise
30 Nucleic acid-based therapeutics18 Nano-engineering
29 Targeted delivery of nanomedicine
19 mRNA therapeutics
14 Autoimmunity
2b Cancer Immunology and Immunotherapy
8
1b Research Interests:
2fd Our lab develops novel nucleic acid delivery systems, including a new generation of targeted lipid nanoparticle (tLNP), for in vivo cellular reprogramming. We leverage these systems for mRNA-based therapeutics in a variety of non-vaccine applications such as inherited diseases, acquired or congenital hematopoietic conditions, cancers, fibrosis, and acute inflammatory conditions. We also investigate the mechanisms underlying the enhancement of delivery systems such as the ones related to more favorable pharmacokinetic profile, to apply those principles in designing more effective gene and mRNA therapeutics. Currently, the targeted LNP-mRNA platform we design serves as the foundation for ongoing academic programs and industrial product developments.
e 29
23
217 Yashaswini CN, Cogliati B, Qin T, To T, Williamson T, Papp TE, Li K, Rasul R, Chen L, Lightstone A, Aghajanian H, Parhiz H, Wang S, Rurik JG, Epstein JA, Friedman SL.: Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis. Sci Transl Med 18: eadx0368, Jan 2026 Notes: Middle author contribution: I provided data sets, analysis, contributed text, and helped revised the manuscript.
136 Hamideh Parhiz: Surface-modified delivery systems for stealth function. In: Harnessing Endogenous Mechanisms for Targeted Drug Delivery. Academic Press. Anisha A. D’Souza, Lara S. Milane and Mansoor M. Amiji (eds.). Elsevier, Jan 2026.
209 Zeng J, Papp TE, Akyianu A, Bahena A, Leo L, Halilovic F, Parhiz H: Rapid receptor internalization potentiates CD7-targeted lipid nanoparticles for efficient mRNA delivery to T cells and in vivo CAR T-cell engineering. bioRxiv Jan 2026 Notes: I led my team here to demonstrate that the efficiency of tLNP was driven by rapid receptor internalization rather than receptor abundance, making internalization kinetics a key factor for optimal delivery.
1b1 Nakamichi S, von Muhlinen N, Yamada L, Melamed JR, Papp TE, Parhiz H, Weissman D, Horikawa I, Harris CC: SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer. Carcinogenesis Nov 2025 Notes: Middle-Author Contribution: I provided data sets, analysis, contributed text, and helped revised the manuscript.
1da Reyes-Esteves S, Majumder A, Marzolini N, Zamora M, Wang Y, Espy C, Papp TE, Akyianu A, Nong J, Messe L, Omo-Lamai S, Parhiz H, Myerson J, Marcos-Contreras O, Brenner J.: Targeted lipid nanoparticles containing IL-10 mRNA improve outcomes in experimental intracerebral hemorrhage. J Neuroinflammation Oct 2025 Notes: I provided data sets, analysis, contributed text, and helped revised the manuscript.
16a A. Aicher, E. Niemeyer, P. Areesawangkit, C. Tilsed, K.P. Fong, X. Shi, J. Zeng, T.E. Papp, H. Parhiz, J. Predina.: Induction of Immunogenic Cancer Cell Death via mRNA Lipid Nanoparticle Treatment. Owen H. Wangensteen Scientific Forum, Am. College of Surgeons Clin. Congress 2025 Oct 2025.
2f0 Omo-Lamai S, Wang Y, Patel MN, Milosavljevic A, Zuschlag D, Poddar S, Wu J, Wang L, Dong F, Espy C, Majumder A, Essien EO, Shen M, Channer B, Papp TE, Tobin M, Maheshwari R, Jeong S, Patel S, Shah A, Murali S, Chase LS, Zamora ME, Arral ML, Marcos-Contreras OA, Myerson JW, Hunter CA, Discher D, Gaskill PJ, Tsourkas A, Muzykantov VR, Brodsky I, Shin S, Whitehead KA, Parhiz H, Katzen J, Miner JJ, Trauner D, Brenner JS.: Limiting endosomal damage sensing reduces inflammation triggered by lipid nanoparticle endosomal escape. Nat Nanotechnol 20(9), Sept 2025 Notes: Middle author contribution: I provided data sets, analysis, contributed text, and helped revised the manuscript.
2b7 Shuvaev VV, Tam YK, Lee BW, Myerson JW, Herbst A, Kiseleva RY, Glassman PM, Parhiz H, Alameh MG, Pardi N, Muramatsu H, Shuvaeva TI, Arguiri E, Marcos-Contreras OA, Hood ED, Brysgel TV, Nong J, Papp TE, Eaton DM, Riley R, Palanki R, Musunuru K, Brenner JS, Mitchell MJ, Ferrari VA, Mui BL, Semple SC, Weppler SA, Atluri P, Margulies KB, Weissman D, Muzykantov VR.: Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo. Proc Natl Acad Sci U S A 122(29): e2409266122, Jul 2025 Notes: I provided data sets, analysis, contributed text, and helped revised the manuscript.
257 Papp TE, Zeng J, Shahnawaz H, Akyianu A, Breda L, Yadegari A, Steward J, Shi R, Li Q, Mui BL, Tam YK, Weissman D, Rivella S, Shuvaev V, Muzykantov VR, Parhiz H.: CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery. Mol Ther 33(7): 3195-3208, Jul 2025 Notes: In this paper, I led the team as corresponding author in further developing our previous studies on the off-target effects of LNP delivery systems and created strategies to reduce these effects and improve the safety profile of LNP treatments.
2c
7
1d
1f
Selected Publications
b6 Bajbouj K, Xiao Z, Todd L, Huang L, Papp TE, Halilovic F, Ramani J, Bao Y, Butcher M, Bot A, Aghajanian H, June CH, Weissman D, Parhiz H, 14a Albelda SA, Pure E. : Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-Cell Engineering Against Pancreatic Tumors. Cancer Immunology Research Feb 2026 Notes: Middle author contribution: I provided data sets, analysis, contributed text, and helped revised the manuscript.217 Yashaswini CN, Cogliati B, Qin T, To T, Williamson T, Papp TE, Li K, Rasul R, Chen L, Lightstone A, Aghajanian H, Parhiz H, Wang S, Rurik JG, Epstein JA, Friedman SL.: Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis. Sci Transl Med 18: eadx0368, Jan 2026 Notes: Middle author contribution: I provided data sets, analysis, contributed text, and helped revised the manuscript.
136 Hamideh Parhiz: Surface-modified delivery systems for stealth function. In: Harnessing Endogenous Mechanisms for Targeted Drug Delivery. Academic Press. Anisha A. D’Souza, Lara S. Milane and Mansoor M. Amiji (eds.). Elsevier, Jan 2026.
209 Zeng J, Papp TE, Akyianu A, Bahena A, Leo L, Halilovic F, Parhiz H: Rapid receptor internalization potentiates CD7-targeted lipid nanoparticles for efficient mRNA delivery to T cells and in vivo CAR T-cell engineering. bioRxiv Jan 2026 Notes: I led my team here to demonstrate that the efficiency of tLNP was driven by rapid receptor internalization rather than receptor abundance, making internalization kinetics a key factor for optimal delivery.
1b1 Nakamichi S, von Muhlinen N, Yamada L, Melamed JR, Papp TE, Parhiz H, Weissman D, Horikawa I, Harris CC: SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer. Carcinogenesis Nov 2025 Notes: Middle-Author Contribution: I provided data sets, analysis, contributed text, and helped revised the manuscript.
1da Reyes-Esteves S, Majumder A, Marzolini N, Zamora M, Wang Y, Espy C, Papp TE, Akyianu A, Nong J, Messe L, Omo-Lamai S, Parhiz H, Myerson J, Marcos-Contreras O, Brenner J.: Targeted lipid nanoparticles containing IL-10 mRNA improve outcomes in experimental intracerebral hemorrhage. J Neuroinflammation Oct 2025 Notes: I provided data sets, analysis, contributed text, and helped revised the manuscript.
16a A. Aicher, E. Niemeyer, P. Areesawangkit, C. Tilsed, K.P. Fong, X. Shi, J. Zeng, T.E. Papp, H. Parhiz, J. Predina.: Induction of Immunogenic Cancer Cell Death via mRNA Lipid Nanoparticle Treatment. Owen H. Wangensteen Scientific Forum, Am. College of Surgeons Clin. Congress 2025 Oct 2025.
2f0 Omo-Lamai S, Wang Y, Patel MN, Milosavljevic A, Zuschlag D, Poddar S, Wu J, Wang L, Dong F, Espy C, Majumder A, Essien EO, Shen M, Channer B, Papp TE, Tobin M, Maheshwari R, Jeong S, Patel S, Shah A, Murali S, Chase LS, Zamora ME, Arral ML, Marcos-Contreras OA, Myerson JW, Hunter CA, Discher D, Gaskill PJ, Tsourkas A, Muzykantov VR, Brodsky I, Shin S, Whitehead KA, Parhiz H, Katzen J, Miner JJ, Trauner D, Brenner JS.: Limiting endosomal damage sensing reduces inflammation triggered by lipid nanoparticle endosomal escape. Nat Nanotechnol 20(9), Sept 2025 Notes: Middle author contribution: I provided data sets, analysis, contributed text, and helped revised the manuscript.
2b7 Shuvaev VV, Tam YK, Lee BW, Myerson JW, Herbst A, Kiseleva RY, Glassman PM, Parhiz H, Alameh MG, Pardi N, Muramatsu H, Shuvaeva TI, Arguiri E, Marcos-Contreras OA, Hood ED, Brysgel TV, Nong J, Papp TE, Eaton DM, Riley R, Palanki R, Musunuru K, Brenner JS, Mitchell MJ, Ferrari VA, Mui BL, Semple SC, Weppler SA, Atluri P, Margulies KB, Weissman D, Muzykantov VR.: Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo. Proc Natl Acad Sci U S A 122(29): e2409266122, Jul 2025 Notes: I provided data sets, analysis, contributed text, and helped revised the manuscript.
257 Papp TE, Zeng J, Shahnawaz H, Akyianu A, Breda L, Yadegari A, Steward J, Shi R, Li Q, Mui BL, Tam YK, Weissman D, Rivella S, Shuvaev V, Muzykantov VR, Parhiz H.: CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery. Mol Ther 33(7): 3195-3208, Jul 2025 Notes: In this paper, I led the team as corresponding author in further developing our previous studies on the off-target effects of LNP delivery systems and created strategies to reduce these effects and improve the safety profile of LNP treatments.
2c
4d
22
22
7
10
a
a
2
2
19
18
10
22
10
11
c
5b © The Trustees of the University of Pennsylvania | Site best viewed a in a supported browser. | Site Design: 57 PMACS Web Team. 3 22
10